The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
暂无分享,去创建一个
S. Shariat | P. Karakiewicz | D. Enikeev | P. Glybochko | D. D’andrea | A. Haitel | H. Fajkovic | M. Abufaraj | M. Rink | P. Nyirády | V. Seebacher | T. Iwata | S. Kimura | F. Janisch
[1] M. Remzi,et al. Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. , 2019, European urology.
[2] Anirban P. Mitra,et al. Molecular markers in bladder cancer , 2008, Current opinion in urology.
[3] M. Babjuk,et al. A systematic review and meta‐analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens , 2018, BJU international.
[4] S. Shariat,et al. Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder , 2018, World Journal of Urology.
[5] S. Shariat,et al. Characteristics and clinical significance of histological variants of bladder cancer , 2017, Nature reviews. Urology.
[6] J. Witjes,et al. MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER , 2016 .
[7] Maximilian Burger,et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.
[8] A. Briganti,et al. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder , 2016, Nature Reviews Urology.
[9] I. Christensen,et al. uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder – Possible Clinical Implications , 2015, PloS one.
[10] A. Vickers,et al. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. , 2015, European urology.
[11] I. Christensen,et al. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder. , 2015, Urologic oncology.
[12] Yair Lotan,et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. , 2015, European urology.
[13] Nicholas D James,et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. , 2014, European urology.
[14] M. Rubin,et al. Frequent truncating mutations of STAG2 in bladder cancer , 2013, Nature Genetics.
[15] F. Montorsi,et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. , 2013, Cancer epidemiology.
[16] Y. Lotan,et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. , 2012, European urology.
[17] C. Dinney,et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort , 2011, BJU international.
[18] H. Grossman,et al. Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. , 2010, Urology.
[19] M. Milowsky,et al. Bladder cancer in the elderly. , 2009, Urologic oncology.
[20] C. Roehrborn,et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. , 2009, European urology.
[21] Aamir Ahmad,et al. Evolving role of uPA/uPAR system in human cancers. , 2008, Cancer treatment reviews.
[22] Yair Lotan,et al. Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy , 2006, Clinical Cancer Research.
[23] Yair Lotan,et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. , 2006, The Journal of urology.
[24] S. Loening,et al. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. , 2004, Oncology reports.
[25] C. Roehrborn,et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. , 2004, The Journal of urology.
[26] S. Shariat,et al. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. , 2003, Urology.
[27] T. Wheeler,et al. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. , 2003, Urology.
[28] G. Steineck,et al. Expression of UPA and UPAR is associated with the clinical course of urinary bladder neoplasms , 2002, International journal of cancer.
[29] M. Kattan,et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. , 2001, The Journal of urology.
[30] A. Sumiyoshi,et al. The content of urokinase‐type plasminogen activator antigen as a prognostic factor in urinary bladder cancer , 1992, International journal of cancer.